CORTAnother reminder from the lawsuit machine
Corcept Therapeutics is back in the headlines, but not for a clean FDA win or a shiny new drug launch. ClaimsFiler is reminding investors that the lead plaintiff deadline in a securities class action lands on April 21, 2026.
What the lawsuit is about
The complaint says Corcept painted a pretty upbeat picture for relacorilant, one of its lead new product candidates, even as the FDA story was heading for a brick wall.
According to the filing, investors were led to believe approval was likely after the NDA submission. Then on December 31, 2025, Corcept said the FDA had issued a Complete Response Letter and wanted more evidence of effectiveness before it could approve the drug.
Why investors should care
Legal headlines like this are annoying, slow-moving, and very much capable of hanging over a stock like a rain cloud at a backyard wedding. Even if the business itself keeps operating, class actions can:
- keep sentiment sour
- raise legal costs
- revive questions about disclosure and execution
In other words, this isn’t just courtroom theater. It can affect how investors value the company while the case works its way through the system.
Big picture: Corcept’s core issue here isn’t just the lawsuit — it’s the gap between what investors expected from relacorilant and what the FDA actually delivered.